PRINT OUT

Product Pipeline

Aug 07. 2018

<Domestic>

Stage Code No.
(Generic name)
Therapeutic field Indications Origin Development
Preparation for launching GA101
(obinutuzumab)
hematologic malignancies CD20-positive follicular lymphoma Licensed - in from
Chugai Pharmaceutical Co., Ltd.
Co - developed with
Chugai Pharmaceutical Co., Ltd.
Preparation for NDA NS-73
(defibrotide)
hematologic malignancies veno-occlusive disease (treatment) Licensed - in from
Jazz Pharmaceuticals plc
Nippon shinyaku
Phase III NS-73
(defibrotide)
hematologic malignancies veno-occlusive disease (prevention) Licensed - in from
Jazz Pharmaceuticals plc
Co - developed with
Jazz Pharmaceuticals plc
Phase III NS-304
(selexipag)
intractable disease・orphan disease chronic thromboembolic pulmonary
hypertension
Nippon shinyaku Co - developed with 
Actelion Pharmaceuticals Japan Ltd.
Phase II NS-304
(selexipag)
cardiovascular arteriosclerosis obliterans Nippon shinyaku Nippon shinyaku
Phase II NS-304
(selexipag)
orthopedics lumbar spinal stenosis Nippon shinyaku Nippon shinyaku
Phase II NS-580 gynecology endometriosis Nippon shinyaku Nippon shinyaku
Phase II NS-17
(azacitidine)
hematologic malignancies acute myeloid leukemia Licensed - in from
Celgene Corporation
Nippon shinyaku
Phase I/II NS-065/
NCNP-01
intractable disease・orphan disease Duchenne muscular dystrophy Co - development:
National Center of Neurology and Psychiatry
Nippon shinyaku
Phase I NS-32 gynecology iron deficiency anemia Licensed - in from
Pharmacosmos A/S
Nippon shinyaku
Preparation for development NS-917 hematologic malignancies relapsed/refractory acute myeloid leukemia Licensed - in from
Delta-Fly Pharma, Inc.
Nippon shinyaku
Preparation for development NS-87 hematologic malignancies secondary acute myeloid leukemia Licensed - in from
Jazz Pharmaceuticals plc
Nippon shinyaku

<Overseas>

Stage Code No.
(Generic name)
Therapeutic field Indications Origin Development
China
NDA filing
NM441
(prulifloxacin)
anti-infection bacterial infections Nippon shinyaku Licensed - out to
Lee's Pharmaceutical Holdings Limited
Phase II NS-065/
NCNP-01
intractable disease・orphan disease Duchenne muscular dystrophy Co - development:
National Center of Neurology and Psychiatry
Nippon shinyaku
Phase I/II NS-018 hematologic malignancies myelofibrosis Nippon shinyaku Nippon shinyaku
page-top